ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0236

What Ultrasound Skills Can Be Learned Before Laying Hands on a Probe? Results of a Pilot Study of a Hybrid Online and in Person Curriculum to Teach Rheumatology Focused Knee Ultrasonography Skills to Internal Medicine Residents

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0237

Whats Trending? A 12- year Analysis of International Medical Graduates Matching into Rheumatology Fellowship Programs in the United States

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0217

Where Are the Reporting Guidelines in Rheumatology? An Analysis of Their Use in over 850 Published Manuscripts

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0368

Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0475

Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: PP01

Why Communication Is the Most Important Thing in Healthcare

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0025

Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0071

Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

3:00PM-4:00PM: Abstract Number: 0498

A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis

Abstracts: RA – Etiology and Pathogenesis

3:00PM-4:30PM: Abstract Number: 0524

A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated

3:00PM-4:30PM: Abstract Number: 0518

Changes in Skin Fibroblast Polarization Gene Expression Herald Clinical Improvement in Early, Diffuse Cutaneous Systemic Sclerosis

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:30PM: Abstract Number: 0526

Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

Abstracts: Vasculitis – ANCA-Associated

3:00PM-4:30PM: Abstract Number: 0522

Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis from EUSTAR

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:30PM: Abstract Number: 0520

Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:30PM: Abstract Number: 0529

Complex Relationships Between Inflammation and Clonal Hematopoiesis in Systemic Vasculitis

Abstracts: Vasculitis – ANCA-Associated

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].